Literature DB >> 28249163

Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates.

Kevin O Saunders1, Nathan I Nicely2, Kevin Wiehe2, Mattia Bonsignori2, R Ryan Meyerhoff3, Robert Parks2, William E Walkowicz4, Baptiste Aussedat4, Nelson R Wu2, Fangping Cai2, Yusuf Vohra4, Peter K Park4, Amanda Eaton5, Eden P Go6, Laura L Sutherland2, Richard M Scearce2, Dan H Barouch7, Ruijun Zhang2, Tarra Von Holle2, R Glenn Overman2, Kara Anasti2, Rogier W Sanders8, M Anthony Moody9, Thomas B Kepler10, Bette Korber11, Heather Desaire6, Sampa Santra12, Norman L Letvin12, Gary J Nabel13, David C Montefiori14, Georgia D Tomaras15, Hua-Xin Liao2, S Munir Alam2, Samuel J Danishefsky4, Barton F Haynes16.   

Abstract

Induction of broadly neutralizing antibodies (bnAbs) that target HIV-1 envelope (Env) is a goal of HIV-1 vaccine development. A bnAb target is the Env third variable loop (V3)-glycan site. To determine whether immunization could induce antibodies to the V3-glycan bnAb binding site, we repetitively immunized macaques over a 4-year period with an Env expressing V3-high mannose glycans. Env immunizations elicited plasma antibodies that neutralized HIV-1 expressing only high-mannose glycans-a characteristic shared by early bnAb B cell lineage members. A rhesus recombinant monoclonal antibody from a vaccinated macaque bound to the V3-glycan site at the same amino acids as broadly neutralizing antibodies. A structure of the antibody bound to glycan revealed that the three variable heavy-chain complementarity-determining regions formed a cavity into which glycan could insert and neutralized multiple HIV-1 isolates with high-mannose glycans. Thus, HIV-1 Env vaccination induced mannose-dependent antibodies with characteristics of V3-glycan bnAb precursors.
Copyright © 2017 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HIV; V3 glycan; glycan; long-term immunization; vaccination

Mesh:

Substances:

Year:  2017        PMID: 28249163      PMCID: PMC5408352          DOI: 10.1016/j.celrep.2017.02.003

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  80 in total

1.  A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.

Authors:  Devin Sok; Matthias Pauthner; Bryan Briney; Jeong Hyun Lee; Karen L Saye-Francisco; Jessica Hsueh; Alejandra Ramos; Khoa M Le; Meaghan Jones; Joseph G Jardine; Raiza Bastidas; Anita Sarkar; Chi-Hui Liang; Sachin S Shivatare; Chung-Yi Wu; William R Schief; Chi-Huey Wong; Ian A Wilson; Andrew B Ward; Jiang Zhu; Pascal Poignard; Dennis R Burton
Journal:  Immunity       Date:  2016-07-19       Impact factor: 31.745

2.  CHARMM-GUI: a web-based graphical user interface for CHARMM.

Authors:  Sunhwan Jo; Taehoon Kim; Vidyashankara G Iyer; Wonpil Im
Journal:  J Comput Chem       Date:  2008-08       Impact factor: 3.376

Review 3.  The role of antibodies in HIV vaccines.

Authors:  John R Mascola; David C Montefiori
Journal:  Annu Rev Immunol       Date:  2010       Impact factor: 28.527

4.  Nucleotide insertions and deletions complement point mutations to massively expand the diversity created by somatic hypermutation of antibodies.

Authors:  Peter M Bowers; Petra Verdino; Zhengyuan Wang; Jean da Silva Correia; Mark Chhoa; Griffin Macondray; Minjee Do; Tamlyn Y Neben; Robert A Horlick; Robyn L Stanfield; Ian A Wilson; David J King
Journal:  J Biol Chem       Date:  2014-10-15       Impact factor: 5.157

5.  Antibody neutralization and escape by HIV-1.

Authors:  Xiping Wei; Julie M Decker; Shuyi Wang; Huxiong Hui; John C Kappes; Xiaoyun Wu; Jesus F Salazar-Gonzalez; Maria G Salazar; J Michael Kilby; Michael S Saag; Natalia L Komarova; Martin A Nowak; Beatrice H Hahn; Peter D Kwong; George M Shaw
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

6.  HIV-1 Neutralizing Antibodies with Limited Hypermutation from an Infant.

Authors:  Cassandra A Simonich; Katherine L Williams; Hans P Verkerke; James A Williams; Ruth Nduati; Kelly K Lee; Julie Overbaugh
Journal:  Cell       Date:  2016-06-23       Impact factor: 41.582

Review 7.  Antiviral antibody responses: the two extremes of a wide spectrum.

Authors:  Lars Hangartner; Rolf M Zinkernagel; Hans Hengartner
Journal:  Nat Rev Immunol       Date:  2006-03       Impact factor: 53.106

Review 8.  A Blueprint for HIV Vaccine Discovery.

Authors:  Dennis R Burton; Rafi Ahmed; Dan H Barouch; Salvatore T Butera; Shane Crotty; Adam Godzik; Daniel E Kaufmann; M Juliana McElrath; Michel C Nussenzweig; Bali Pulendran; Chris N Scanlan; William R Schief; Guido Silvestri; Hendrik Streeck; Bruce D Walker; Laura M Walker; Andrew B Ward; Ian A Wilson; Richard Wyatt
Journal:  Cell Host Microbe       Date:  2012-10-18       Impact factor: 21.023

9.  PBEQ-Solver for online visualization of electrostatic potential of biomolecules.

Authors:  Sunhwan Jo; Miklos Vargyas; Judit Vasko-Szedlar; Benoît Roux; Wonpil Im
Journal:  Nucleic Acids Res       Date:  2008-05-28       Impact factor: 16.971

10.  Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors.

Authors:  Thomas B Kepler
Journal:  F1000Res       Date:  2013-04-03
View more
  36 in total

1.  Signature-Ion-Triggered Mass Spectrometry Approach Enabled Discovery of N- and O-Linked Glycosylated Neuropeptides in the Crustacean Nervous System.

Authors:  Qinjingwen Cao; Qing Yu; Yang Liu; Zhengwei Chen; Lingjun Li
Journal:  J Proteome Res       Date:  2020-01-13       Impact factor: 4.466

Review 2.  Targeting the N332-supersite of the HIV-1 envelope for vaccine design.

Authors:  Thandeka Moyo; Dale Kitchin; Penny L Moore
Journal:  Expert Opin Ther Targets       Date:  2020-04-27       Impact factor: 6.902

3.  HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.

Authors:  David Easterhoff; Justin Pollara; Kan Luo; Benjamin Janus; Neelakshi Gohain; LaTonya D Williams; Matthew Zirui Tay; Anthony Monroe; Kristina Peachman; Misook Choe; Susie Min; Paolo Lusso; Peng Zhang; Eden P Go; Heather Desaire; Mattia Bonsignori; Kwan-Ki Hwang; Charles Beck; Matina Kakalis; Robert J O'Connell; Sandhya Vasan; Jerome H Kim; Nelson L Michael; Jean-Louis Excler; Merlin L Robb; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Sorachai Nitayaphan; Faruk Sinangil; James Tartaglia; Sanjay Phogat; Kevin Wiehe; Kevin O Saunders; David C Montefiori; Georgia D Tomaras; M Anthony Moody; James Arthos; Mangala Rao; M Gordon Joyce; Gilad Ofek; Guido Ferrari; Barton F Haynes
Journal:  JCI Insight       Date:  2020-01-30

4.  Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models.

Authors:  Kevin O Saunders; Laurent K Verkoczy; Chuancang Jiang; Jinsong Zhang; Robert Parks; Haiyan Chen; Max Housman; Hilary Bouton-Verville; Xiaoying Shen; Ashley M Trama; Richard Scearce; Laura Sutherland; Sampa Santra; Amanda Newman; Amanda Eaton; Kai Xu; Ivelin S Georgiev; M Gordon Joyce; Georgia D Tomaras; Mattia Bonsignori; Steven G Reed; Andres Salazar; John R Mascola; M Anthony Moody; Derek W Cain; Mireille Centlivre; Sandra Zurawski; Gerard Zurawski; Harold P Erickson; Peter D Kwong; S Munir Alam; Yves Levy; David C Montefiori; Barton F Haynes
Journal:  Cell Rep       Date:  2017-12-26       Impact factor: 9.423

Review 5.  Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

Authors:  Raiees Andrabi; Jinal N Bhiman; Dennis R Burton
Journal:  Curr Opin Immunol       Date:  2018-05-16       Impact factor: 7.486

6.  Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor.

Authors:  S Munir Alam; Kenneth Cronin; Robert Parks; Kara Anasti; Haitao Ding; Eden P Go; Heather Desaire; Amanda Eaton; David Montefiori; Joseph Sodroski; John Kappes; Barton F Haynes; Kevin O Saunders
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

7.  Synthetic Three-Component HIV-1 V3 Glycopeptide Immunogens Induce Glycan-Dependent Antibody Responses.

Authors:  Hui Cai; Jared Orwenyo; John P Giddens; Qiang Yang; Roushu Zhang; Celia C LaBranche; David C Montefiori; Lai-Xi Wang
Journal:  Cell Chem Biol       Date:  2017-10-26       Impact factor: 8.116

8.  Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition.

Authors:  Hui Cai; Rou-Shu Zhang; Jared Orwenyo; John Giddens; Qiang Yang; Celia C LaBranche; David C Montefiori; Lai-Xi Wang
Journal:  J Med Chem       Date:  2018-11-08       Impact factor: 7.446

9.  Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.

Authors:  Kevin O Saunders; Kevin Wiehe; Ming Tian; Priyamvada Acharya; Todd Bradley; S Munir Alam; Eden P Go; Richard Scearce; Laura Sutherland; Rory Henderson; Allen L Hsu; Mario J Borgnia; Haiyan Chen; Xiaozhi Lu; Nelson R Wu; Brian Watts; Chuancang Jiang; David Easterhoff; Hwei-Ling Cheng; Kelly McGovern; Peyton Waddicor; Aimee Chapdelaine-Williams; Amanda Eaton; Jinsong Zhang; Wes Rountree; Laurent Verkoczy; Mark Tomai; Mark G Lewis; Heather R Desaire; Robert J Edwards; Derek W Cain; Mattia Bonsignori; David Montefiori; Frederick W Alt; Barton F Haynes
Journal:  Science       Date:  2019-12-06       Impact factor: 47.728

10.  Automated Design by Structure-Based Stabilization and Consensus Repair to Achieve Prefusion-Closed Envelope Trimers in a Wide Variety of HIV Strains.

Authors:  Reda Rawi; Lucy Rutten; Yen-Ting Lai; Adam S Olia; Sven Blokland; Jarek Juraszek; Chen-Hsiang Shen; Yaroslav Tsybovsky; Raffaello Verardi; Yongping Yang; Baoshan Zhang; Tongqing Zhou; Gwo-Yu Chuang; Peter D Kwong; Johannes P M Langedijk
Journal:  Cell Rep       Date:  2020-11-24       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.